Kite and Shoreline Biosciences enter partnership to develop novel allogeneic cell therapies EP News Bureau Jun 17, 2021 Partnership follows Kite’s investment in Shoreline’s recent Series A financing
Kite gets US FDA nod for Yescarta to treat relapsed or refractory follicular lymphoma EP News Bureau Mar 6, 2021 Yescarta is the first CAR T-Cell therapy approved for indolent follicular lymphoma
